Testing an oral drug for cold virus in COPD patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests an oral medication (VPV) to see if it can safely treat rhinovirus (a common cold virus) in people with COPD. The goal is to help you recover faster and prevent serious COPD flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 to 85 years old.
- You have been diagnosed with COPD (chronic lung disease).
- You have had at least one flare-up of COPD in the past year.
- You are willing to take a test to check for a rhinovirus (cold virus) infection.
- You are not currently pregnant or nursing, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the common cold virus affects people with COPD to find new treatments. If you have moderate COPD and your symptoms flare up when you catch a cold, you may be able to help.
This study tests whether giving a common cold virus (rhinovirus) to people with bronchiectasis and healthy volunteers can trigger a lung flare-up. It aims to understand how the immune system responds and what causes exacerbations, which could lead to better treatments.
This trial tests a new drug, BBT002, first in healthy volunteers and then in people with chronic obstructive pulmonary disease (COPD) or chronic sinusitis with nasal polyps. It aims to see if the drug is safe and how it works in the body.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This trial tests if an investigational nasal spray (ETH47) can reduce asthma symptoms triggered by a common cold virus (rhinovirus). You will be exposed to the virus in a safe setting to see if the spray helps control your asthma.
Hear when a new Rhinovirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.